Drug Profile
Research programme: prostate cancer therapeutic - Janssen/Parabon NanoLabs
Alternative Names: PJ-01Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Parabon NanoLabs
- Developer Janssen Research & Development; Parabon NanoLabs
- Class
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in USA
- 04 Dec 2012 Preclinical trials in Prostate cancer in USA (unspecified route)